Application of lipid nanoparticles to ocular drug delivery
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Although eye drops are widely used as drug delivery systems for the anterior segment of the eye, they are also associated with poor drug bioavailability due to transient contact time and rapid washout by tearing. Moreover, effective drug delivery to the posterior segment of the eye is challenging, and alternative routes of administration (periocular and intravitreal) are generally needed, the blood-retinal barrier being the major obstacle to systemic drug delivery. Areas covered: Nanotechnology, and especially lipid nanoparticles, can improve the therapeutic efficiency, compliance and safety of ocular drugs, administered via different routes, to both the anterior and posterior segment of the eye. This review highlights the main ocular barriers to drug delivery, as well as the most common eye diseases suitable for pharmacological treatment in which lipid nanoparticles have proved efficacious as alternative delivery systems. Expert opinion: Lipid-based nanocarriers are among the most biocompatible and versatile means for ocular delivery. Mucoadhesion with consequent increase in pre-corneal retention time, and enhanced permeation due to cellular uptake by corneal epithelial cells, are the essential goals for topical lipid nanoparticle delivery. Gene delivery to the retina has shown very promising results after intravitreal administration of lipid nanoparticles as non-viral vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181 · cited 2×
“Lipophilicity, solubility, molecular size, charge, and degree of ionization also affect the route and rate of penetration in the cornea [26].”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Animal models of choroidal and retinal neovascularization
Grossniklaus, H. E., Kang, S. J., & Berglin, L. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.05.003 · Cited by 350 · cited 1×
“Because retinal and choroidal neovascularizations are the main mechanisms related to ARB, suitable animal models have been developed [55].”
The Blood-Retina Barrier: Tight Junctions and Barrier Modulation
Campbell, M., & Humphries, P. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-4711-5_3 · Cited by 270
Proteomic analysis of human vitreous humor
Murthy, K. R., Goel, R., Subbannayya, Y., Jacob, H. K., Murthy, P. R., Manda, S. S., Patil, A. H., Sharma, R., Sahasrabuddhe, N. A., Parashar, A., et al. (2014) · Clinical Proteomics · doi:10.1186/1559-0275-11-29 · Cited by 145
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Self-citationProvost, N., Le Meur, G., Weber, M., Mendes-Madeira, A., Podevin, G., Cherel, Y., Colle, M.-A., Deschamps, J.-Y., Moullier, P., & Rolling, F. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.022 · Cited by 87
Pharmacological management of ocular hypertension: current approaches and future prospective
Bucolo, C., Salomone, S., Drago, F., Reibaldi, M., Longo, A., & Uva, M. G. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.09.012 · Cited by 71 · cited 1×
“Innovative ‘inflow’ (hydroxysteroid dehydrogenase-1 inhibitors; melatonin) and ‘outflow’ agents (dopamine, serotonine and adenosine agonists, cannabinoids) are currently under study [42,43].”
Cited by
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery
Majumder, J., & Minko, T. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1828339 · Cited by 348
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
“SLNs, as unique delivery systems encapsulating active pharmaceuticals for the treatment of CNS disorders, can be delivered via oral, inhalational, and parenteral routes [188] to reach the neuronal sites.”
Early and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Metadata
- Authors
- Battaglia, L., Serpe, L., Foglietta, F., Muntoni, E., Gallarate, M., Del Pozo Rodriguez, A., & Solinis, M. A.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2016-06-24
- Volume
- 13
- Issue
- 12
- Pages
- 1743-1757
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2437504278
- Cited by
- 152
- References
- 9
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Application of lipid nanoparticles to ocular drug delivery. https://app.cochat.ai/papers/10.1080/17425247.2016.1201059
- The paper
- Battaglia, L., Serpe, L., Foglietta, F., Muntoni, E., Gallarate, M., Del Pozo Rodriguez, A., & Solinis, M. A. (2016). Application of lipid nanoparticles to ocular drug delivery. Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2016.1201059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.